PCM
ONC icon

Prelude Capital Management’s BeOne Medicines Ltd ONC Stock Holding History

Prelude Capital Management’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,300
Closed -$613K – 1586
2024
Q2 		$613K Sell
4,300
-2,700
-39% -$416K 0.04% 455
2024
Q1 		$1.09M Buy
+7,000
New +$1.13M 0.06% 374
2023
Q1 		– Sell
-3,300
Closed -$726K – 1514
2022
Q4 		$726K Buy
+3,300
New +$605K 0.04% 448
2018
Q4 		– Sell
-1,916
Closed -$330K – 2228
2018
Q3 		$330K Buy
1,916
+982
+105% +$165K 0.02% 645
2018
Q2 		$144K Buy
+934
New +$167K 0.01% 835

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Prelude Capital Management's ONC Position: Q3 2024 in Review

Prelude Capital Management sold out of BeOne Medicines Ltd (ONC) in Q3 2024, closing a stake of 4,300 shares — an estimated $613K sold.

Prelude Capital Management first reported a position in ONC in Q2 2018 and held it in 5 quarters. The position peaked at $1.09M in Q1 2024. 228 funds tracked by Wall St. Rank hold ONC as of Q3 2024.

  • Prelude Capital Management reported no remaining BeOne Medicines Ltd position as of Q3 2024 after selling out during the quarter.
  • Prelude Capital Management sold 4,300 BeOne Medicines Ltd shares in Q3 2024, an estimated $613K.
  • Prelude Capital Management first reported a position in BeOne Medicines Ltd in Q2 2018 and held it in 5 quarters.
  • Prelude Capital Management's BeOne Medicines Ltd position peaked at $1.09M in Q1 2024.
  • 228 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2024.

Based on Prelude Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.